MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ: MLTX (MoonLake Immunotherapeutics)
Kemas kini terakhir: 1 jam lalu11.41
-0.06 (-0.52%)
| Penutupan Terdahulu | 11.47 |
| Jumlah Dagangan | 1,827,763 |
| Harga / Buku (P/B) | 2.56 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -2.30 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.32% |
| Nisbah Semasa (MRQ) | 21.11 |
| Aliran Tunai Operasi (OCF TTM) | -139.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -102.40 M |
| Pulangan Atas Aset (ROA TTM) | -19.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | MoonLake Immunotherapeutics | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 1.17 |
|
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 15.34% |
| % Dimiliki oleh Institusi | 96.70% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |